MedTrace Logo

Phenotyping and Characterization of wtATTR-CM (TRACE 1)

NCT06291805 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-08-15

No results posted yet for this study

Summary

Descriptive cross-sectional study on 100 consecutive ATTRwt-CM patients reflecting all NAC stages aiming primarily to investigate ATTRwt-CM patient's quality of life (QoL) measures and their relation to ATTRwt-CM severity. Secondarily aiming to investigate the possibility to measure misTTR and fragTTR in plasma and urine and to detect fragTTR in endomyocardial biopsies from ATTRwt-CM patients. To investigate whether misTTR and fragTTR levels are correlated with ATTRwt-CM severity.

Conditions

  • Transthyretin Amyloidosis
  • Transthyretin Amyloid Cardiomyopathy
  • Wild-Type Transthyretin-Related (ATTR)Amyloidosis
  • Quality of Life

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-20
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06291805 on ClinicalTrials.gov